ENSG vs ZBH
Ensign Group vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | ENSG | ZBH |
|---|
| AI Score |
68
|
70
|
| Price |
$182.93
|
$96.61
|
| P/E Ratio |
27.85×
|
23.38×
|
| ROE |
15.4%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
69.9%
|
| Debt / Equity |
0.92×
|
0.59×
|
| Dividend Yield |
0.1%
|
1.0%
|
| RSI (14) |
70.0
|
58.9
|
| Beta |
0.689
|
0.468
|
| Expected Upside |
+5.9%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for ENSG versus ZBH.
ZBH leads by 2 points.
ZBH scores 70/100 (Buy) versus ENSG at 68/100 (Buy).
ENSG Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.